News & Press Releases

Joanne Hawana shared insights with Law360 Healthcare Authority about how drugmakers are responding to a series of pilot programs launched by the Food and Drug Administration. The new programs include an AI-assisted scientific review process and a program designed to accelerate the drug approval process, among other changes.

Boston Bar Journal published an article co-authored by Member Christopher Lisy and Associate Kayla LaRosa that offers guidance on understanding digital evidence and how to present it to fact-finders most effectively. The attorneys explain how the rise of AI-generated content is creating new challenges, including the prevalence of audio and video “deepfakes”.

Mitch Frazer was featured on the Toronto Metropolitan University’s website for his recent role as a speaker at the university’s “Law + Business: A Strategic Convergence”. The event highlighted a new admission stream created through a collaboration between the Ted Rogers MBA program and the Lincoln Alexander School of Law that allows students to earn a combined Juris Doctor and Master of Business Administration.

Endpoints News featured commentary from Mitchell Clough in an article about the impending deadline for two major drugmakers to appeal Inflation Reduction Act challenges to the US Supreme Court as the first set of negotiated Medicare drug prices is scheduled to take effect on January 1, 2026. While many experts doubt that the Supreme Court will intervene before the January deadline, companies may still hope for eventual rulings that could invalidate or reshape the program.

Eleven Mintz attorneys have been featured in the 2026 edition of the Intellectual Asset Management (IAM) Strategy 300 Global Leaders Guide. This annual guide honors professionals whose peers regard their approach to intellectual property as “truly strategic in nature” and who demonstrate a “wealth of expertise across disciplines and sectors,” according to IAM.

Mintz advised the underwriters in connection with Cogent Biosciences, Inc.’s concurrent public offerings of $345 million of common stock (the “Equity Offering”) and $230 million in aggregated principal amount of 1.625% convertible senior notes due 2031 (the “Convertible Notes Offering”).